SCI Drug Gets FDA Fast-Track

NervGen, also known as NVG-291, recently received the FDA's Fast-Track Designation status to help the drug move quicker through the approval process.

Currently, the drug is in phase 1b/2a which is rodent testing. The researchers behind this drug believe it has the potential to be the first approved treatment to enable neurological recovery. Learn more

NorCal SCI want to recognize our friends at https://spinalpedia.com for alerting us to this article.